CRISPR Therapeutics AG [NASDAQ: CRSP] gained 9.29% or 3.68 points to close at $43.30 with a heavy trading volume of 4228779 shares.
The daily chart for CRSP points out that the company has recorded -7.70% loss over the past six months.
If we look at the average trading volume of 1.91M shares, CRSP reached to a volume of 4228779 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about CRISPR Therapeutics AG [CRSP]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CRSP shares is $79.93 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CRSP stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
TD Cowen have made an estimate for CRISPR Therapeutics AG shares, keeping their opinion on the stock as Hold, with their previous recommendation back on Feb-13-25. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on February 03, 2025, representing the official price target for CRISPR Therapeutics AG stock. Previously, the target price had yet another drop from $88 to $84, while Needham kept a Buy rating on CRSP stock.
The Average True Range (ATR) for CRISPR Therapeutics AG is set at 2.17, with the Price to Sales ratio for CRSP stock in the period of the last 12 months amounting to 99.06. The Price to Book ratio for the last quarter was 1.92, with the Price to Cash per share for the same quarter was set at 22.31.
Trading performance analysis for CRSP stock
CRISPR Therapeutics AG [CRSP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.56. With this latest performance, CRSP shares gained by 11.45% in over the last four-week period, additionally sinking by -7.70% over the last 6 months – not to mention a drop of -38.15% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRSP stock in for the last two-week period is set at 56.08, with the RSI for the last a single of trading hit 61.42, and the three-weeks RSI is set at 52.69 for CRISPR Therapeutics AG [CRSP]. The present Moving Average for the last 50 days of trading for this stock 42.99, while it was recorded at 40.53 for the last single week of trading, and 49.60 for the last 200 days.
CRISPR Therapeutics AG [CRSP]: A deeper dive into fundamental analysis
CRISPR Therapeutics AG’s liquidity data is similarly interesting compelling, with a Quick Ratio of 22.07 and a Current Ratio set at 22.07.
CRISPR Therapeutics AG [CRSP]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CRSP. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for CRISPR Therapeutics AG go to 39.56%.
An analysis of Institutional ownership at CRISPR Therapeutics AG [CRSP]
There are presently around $73.81%, or 75.17%% of CRSP stock, in the hands of institutional investors. The top three institutional holders of CRSP stocks are: CAPITAL INTERNATIONAL INVESTORS with ownership of 7.87 million shares, which is approximately 9.6159%. ARK INVESTMENT MANAGEMENT LLC, holding 7.78 million shares of the stock with an approximate value of $$420.12 million in CRSP stocks shares; and ARK INVESTMENT MANAGEMENT LLC, currently with $$170.21 million in CRSP stock with ownership which is approximately 3.853%.
